A Phase 4 interventional study of Evolocumab in STEMI and Dyslipidemias, sponsored by Hamad Medical Corporation. Status unknown. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-10-13.
Sponsored by Hamad Medical Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Patients with acute coronary syndromes (ACS) have an increased risk of recurrent ischemic events, particularly during the first year following the index event, which is mainly due to unattended risk factors and/ or poor compliance with medications. Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular morbidity and mortality in patients with atherosclerotic cardiovascular disease (ASCVD), with a magnitude of clinical benefit that is proportional to the reduction in LDL-C levels. Proprotein convertase subtilisin/ kexin type 9 (PCSK9) antibodies have emerged as a new class of drugs that rapidly and effectively lower LDL-C levels up to 77 % of the original value in combination with statins.
The primary objective of this study is to confirm the safety and the long-term clinical benefit associated with the use of PCSK9i when combined with statin in patients with ACS-STEMI.
The study is an investigator-initiated, prospective, randomized, open label study that will be the first study looking for the safety and the clinical benefit and outcome associated with the use of PCSK9i in ACS-STEMI patients specifically. Internationally, this will be the first trial studying the effect of PCSK9i on patients with acute myocardial infarction (STEMI) in terms of reduction in cholesterol level and reduction in cardiac events rate (re-infarction and cardiac death) after myocardial infarction. This trial will have a significant impact in the management of patients with STEMI, locally and internationally and it will be conducted purely in Qatar. This trial will help to improve the clinical outcome of patients in Qatar in terms of reduction of myocardial reinfarction rate and mortality.
The study is an investigator-initiated, prospective, randomized, open-label study. Patients will be eligible for participation in the trial if they are between 18-70 years of age. All patients presenting with STEMI will be screened for the trial, those patients with LDL-C levels higher than guideline-recommended targets despite prior high-intensity statin therapy (on statin therapy prior to hospital admission), or when the LDL-C not projected to decrease below the recommended targets if they are newly initiated on high intensity statin therapy, will be considered for the study.
Procedures and study interventions.
LDL- C will be assessed immediately post angiography: The patient will be eligible for the trial if the LDL-C levels at the screening blood test is one of the following:
>1.8 mmol/l if patients are on stable (unchanged for >4 weeks before screening) treatment with high-intensity statin.
2.3 mmol/l in patients previously taking low- or moderate-intensity statin. 3.2 mmol/l in patients not on statin treatment.
Information and investigation that will be collected from patient:
Randomization:
Participants will be randomly assigned using permuted block design with a computer random number generator, the block size is fixed (8 per block) with random allocation within the block to either the control group or the interventional group. of the patients (4 for each group, patient allocation within the block is randomly assigned). Once the patient has given consent to be included in the trial, he/she is then irreversibly randomized by opening the next sealed envelope, within the current block, containing his/her assignment.
The production of computer-generated sets of random allocations will be done by a research support unit (who will not be performing data collection) in advance of the start of the study.
Sample size calculation:
Our study is designed as a superiority trial powered for the primary endpoint. The average LDL-D cholesterol of patients admitted with ACS-STEMI to the Heart Hospital was 3.4 mmol based on calculating the average LDL-C of 150 patients with ACS-STEMI in the past 6 months (department Data).
Bases on the EVOPACS study above, statin alone therapy will reduce the LDL-C by 35 % (1.19 mmol), while Evolocumab + statin combination therapy will reduce LDL-C by 77 % (2.61 mmol). Expectations for cholesterol-lowering trials were set by the Cholesterol Treatment Trialists' Collaborators, who reported in 2005 that for each 1 mmol/L (38.6 mg/dL) reduction in LDL-C, cardiovascular events were reduced by a mean of 22%. Based on this, the expected reduction in cardiovascular event is 26 % with statin therapy alone and 57 % with Evolocumab + statin. Assuming 1000 cases of ACS-STEMI present to our emergency department every year, and event rate of 17-33 % post STEMI patient for those on moderate to high intensity statins at one year, 90 % power and 5 % significance level, the sample size was 144 for each arm. Accounting for the nature of the country of high travel and dropout nature, 20 % drop rate was added to the sample size, the final sample size for this trial was up rounded to 350 patients (originally was 346).
852 studies on the registry are indexed under ST Elevation Myocardial Infarction; 199 are open to participants now.
This study's planned enrollment of 350 is above the median of 194 across 529 interventional studies indexed under ST Elevation Myocardial Infarction.
Browse ST Elevation Myocardial Infarction studies →Hamad Medical Corporation is the lead sponsor of 139 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Inclusion Criteria
LDL-C levels defined as follows:
Exclusion criteria
Reported intolerance to atorvastatin (any dose) OR statin intolerance defined by the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient that qualify for the trial will be randomized for receiving the PCSK9i injection in addition to the standard medical therapy.
Drug: Evolocumab
Patient will only receive the standard medical therapy, No PCSK9i
Evolocumab is an injection for management of dyslipidemia
Also known as: Repatha
Major cardiovascular events, defined as the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.
The primary objective of this study is to confirm the safety and the long-term clinical benefit associated with the use of PCSK9i in combination with statin in patients with ACS-STEMI. The long terms clinical benefit is the reduction in major cardiovascular events, defined as the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.
Time frame: 12 months
The safety of PCSK9i in patients with STEMI
The safety of PCSK9i use in patients admitted with STEMI in terms of adverse events and complications related to the use of PCSK9i.
Time frame: 12 months
Percentage change in calculated LDL-C from baseline to end of study period.
The changes noted in the LDL-C levels from baseline ( time of recruitment) to end of study period.
Time frame: 12 months
Changes in carotid intimal thickening from baseline to the end of study period
The intima-medial thickness of common carotid artery will evaluated by B-mode ultrasound imaging, the delta changes in the carotid intima-medial thickness will be calculated.
Time frame: 12 months
Adverse events and serious adverse events reported during study period.
Any adverse events whether expected or not expected will be record and tabulated. These adverse events will be compared with the control group.
Time frame: 12 months
Changes in High-sensitivity C-reactive protein from baseline to the end of study period
Changes in High-sensitivity C-reactive protein from baseline to the end of study period
Time frame: 12 months
Changes in left ventricular ejection fraction from baseline to the end of study period .
Changes in left ventricular ejection fraction from baseline to the end of study period will be measured using echocardiogram.
Time frame: 12 months
Individual major cardiovascular events, defined as the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.
The effect of PCSK9i use in STEMI patients for each of the outcome individually including: cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.
Time frame: 12 months
No study locations are listed for this record.
Plan to share: Yes — All patients details will be stored in an electronic database and will be shared if a request submitted to institution research board and approved.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: 10 years
Access criteria: Request has to be approved by PI and Heart Hospital Research Advisory Board.
No publications or documents are linked to this record.
Start is estimated for Nov 2022; primary completion for Oct 2024, 23 months later.
Of 49 phase 4 interventional studies under ST Elevation Myocardial Infarction, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab
ST Elevation Myocardial Infarction →